Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 1456-1461 |
| Seitenumfang | 6 |
| Fachzeitschrift | Annals of the rheumatic diseases |
| Jahrgang | 64 |
| Ausgabenummer | 10 |
| Frühes Online-Datum | 30 März 2005 |
| Publikationsstatus | Veröffentlicht - Okt. 2005 |
Abstract
Objective: To determine rheumatoid arthritis related out of pocket expenditure (OOPE) in Germany and to disaggregate the total OOPE into contributing cost domains. Methods: Data for the cost analysis were drawn from a multicentre randomised controlled prospective trial to assess the effectiveness of clinical quality management in patients with rheumatoid arthritis. Both payer sources and patient cost questionnaires were used to generate health care utilisation data. All cost domains of a recently published matrix were reviewed and potential sources of OOPE were determined. Health care utilisation data were developed throughout 2001. Co-payment regulations as per January 2004 were applied in order to indicate the most recent level of OOPE in Germany. Data were analysed in both physical and monetary units using descriptive statistics. Results: In all, 136 patients with rheumatoid arthritis were included. Mean total OOPE per patient and year was €417.20 (SEM 38.8, median 271.2). OOPE accounted for 15.3% of the total direct costs of rheumatoid arthritis. Total OOPE were further subdivided into cost domains: "non-physician service utilisation" (€194.40 per patient and year; SEM 24.2), "medication" (€99.00; 6.1), "transportation" (€56.20; 17.4), "visits to physicians" (€38.40; 0.6), "hospital facilities" (€24.00; 5.6), and "devices and aids" (€5.10; 0.8). Conclusions: Rheumatoid arthritis is associated with substantial OOPE, imposing a considerable economic burden for patients. OOPE contribute significantly to the total health care expenditure in rheumatoic arthritis. The patient perspective has to be taken into account when calculating the overall direct costs of rheumatoid arthritis from a societal point of view.
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Immunologie und Allergologie
- Medizin (insg.)
- Rheumatologie
- Immunologie und Mikrobiologie (insg.)
- Immunologie
- Biochemie, Genetik und Molekularbiologie (insg.)
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Annals of the rheumatic diseases, Jahrgang 64, Nr. 10, 10.2005, S. 1456-1461.
Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Forschung › Peer-Review
}
TY - JOUR
T1 - Direct costs related to rheumatoid arthritis
T2 - the patient perspective
AU - Hülsemann, J. L.
AU - Mittendorf, T.
AU - Merkesdal, S.
AU - Handelmann, S.
AU - Von Der Schulenburg, J. M.
AU - Zeidler, H.
AU - Ruof, J.
AU - Zeh, S.
PY - 2005/10
Y1 - 2005/10
N2 - Objective: To determine rheumatoid arthritis related out of pocket expenditure (OOPE) in Germany and to disaggregate the total OOPE into contributing cost domains. Methods: Data for the cost analysis were drawn from a multicentre randomised controlled prospective trial to assess the effectiveness of clinical quality management in patients with rheumatoid arthritis. Both payer sources and patient cost questionnaires were used to generate health care utilisation data. All cost domains of a recently published matrix were reviewed and potential sources of OOPE were determined. Health care utilisation data were developed throughout 2001. Co-payment regulations as per January 2004 were applied in order to indicate the most recent level of OOPE in Germany. Data were analysed in both physical and monetary units using descriptive statistics. Results: In all, 136 patients with rheumatoid arthritis were included. Mean total OOPE per patient and year was €417.20 (SEM 38.8, median 271.2). OOPE accounted for 15.3% of the total direct costs of rheumatoid arthritis. Total OOPE were further subdivided into cost domains: "non-physician service utilisation" (€194.40 per patient and year; SEM 24.2), "medication" (€99.00; 6.1), "transportation" (€56.20; 17.4), "visits to physicians" (€38.40; 0.6), "hospital facilities" (€24.00; 5.6), and "devices and aids" (€5.10; 0.8). Conclusions: Rheumatoid arthritis is associated with substantial OOPE, imposing a considerable economic burden for patients. OOPE contribute significantly to the total health care expenditure in rheumatoic arthritis. The patient perspective has to be taken into account when calculating the overall direct costs of rheumatoid arthritis from a societal point of view.
AB - Objective: To determine rheumatoid arthritis related out of pocket expenditure (OOPE) in Germany and to disaggregate the total OOPE into contributing cost domains. Methods: Data for the cost analysis were drawn from a multicentre randomised controlled prospective trial to assess the effectiveness of clinical quality management in patients with rheumatoid arthritis. Both payer sources and patient cost questionnaires were used to generate health care utilisation data. All cost domains of a recently published matrix were reviewed and potential sources of OOPE were determined. Health care utilisation data were developed throughout 2001. Co-payment regulations as per January 2004 were applied in order to indicate the most recent level of OOPE in Germany. Data were analysed in both physical and monetary units using descriptive statistics. Results: In all, 136 patients with rheumatoid arthritis were included. Mean total OOPE per patient and year was €417.20 (SEM 38.8, median 271.2). OOPE accounted for 15.3% of the total direct costs of rheumatoid arthritis. Total OOPE were further subdivided into cost domains: "non-physician service utilisation" (€194.40 per patient and year; SEM 24.2), "medication" (€99.00; 6.1), "transportation" (€56.20; 17.4), "visits to physicians" (€38.40; 0.6), "hospital facilities" (€24.00; 5.6), and "devices and aids" (€5.10; 0.8). Conclusions: Rheumatoid arthritis is associated with substantial OOPE, imposing a considerable economic burden for patients. OOPE contribute significantly to the total health care expenditure in rheumatoic arthritis. The patient perspective has to be taken into account when calculating the overall direct costs of rheumatoid arthritis from a societal point of view.
UR - http://www.scopus.com/inward/record.url?scp=27744589307&partnerID=8YFLogxK
U2 - 10.1136/ard.2004.031880
DO - 10.1136/ard.2004.031880
M3 - Review article
C2 - 15800007
AN - SCOPUS:27744589307
VL - 64
SP - 1456
EP - 1461
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
SN - 0003-4967
IS - 10
ER -